Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab-Reference-Cited by-同舟云学术

Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab

Published:2013-12 Issue:3 Volume:113 Page:313-322
ISSN:0168-8510
Container-title:Health Policy
language:en
Short-container-title:Health Policy

Author:

Leopold C.,Vogler S.,Habl C.,Mantel-Teeuwisse A.K.,Espin J.

Publisher

Elsevier BV

Subject

Health Policy

Reference45 articles.

1. A European view on the future of personalised medicine in the EU;Coggi;European Journal of Public Health,2011

2. The foundations of genomic and personalized medicine;Ginsburg,2010

3. The path to personalized medicine;Hamburg;The New England Journal of Medicine,2010

4. Delivering afforable cancer care in high-income countries;Sullivan;The Lancet Oncolocy,2011

5. Drug development for orphan diseases in the context of personalised medicine;Brewer;Translational Research,2009

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation;Personalized Medicine;2023-07

2. Contemporary challenges in the European pharmaceutical industry: a systematic literature review;Measuring Business Excellence;2022-11-08

3. Assessing, Pricing and Funding Point-of-Care Diagnostic Tests for Community-Acquired Acute Respiratory Tract Infections–Overview of Policies Applied in 17 European Countries;Antibiotics;2022-07-22

4. Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options;Applied Health Economics and Health Policy;2022-04-04

5. Challenges and Solutions for Integrating and Financing Personalized Medicine in Healthcare Systems: A Systematic Literature Review;Journal of Risk and Financial Management;2020-11-16